Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Icl Group Ltd (ICL) vs Eli Lilly And Co (LLY) Price & Performance

Icl Group LtdTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Icl Group Ltd vs Eli Lilly And Co — how do they compare? Icl Group Ltd trades at $5.45 (market cap $6.94B), while Eli Lilly And Co trades at $1,199 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 155.6× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (3.86%). Which is the better fit depends on your goals.

ICLLLY
Market Cap
$6.94B$1.08T
Sector
Basic MaterialsHealth
52-Week High
$6.84$1.24K
52-Week Low
$4.80$639.43
Enterprise Value
$9.58B$1.13T
Dividend Yield
3.86%0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Icl Group Ltd

ICL trades at $5.34, up 0.56% today, with a bullish technical signal supported by moving averages. Recent Q2 2026 earnings beat expectations with EPS of $0.12 versus $0.11 expected, continuing a trend of positive surprises. The company maintains stable cash flow from operations around $1.1B annually and pays consistent dividends, with recent payments of $0.05 and $0.06 per share.

Outlook remains cautious with 100% analyst hold ratings citing fair valuation. Risks include declining profit margins (3.95% net margin in 2025) and exposure to commodity price volatility. The stock offers moderate value with P/E of 22.25 and P/S of 0.89, but requires monitoring of cost transformation program effectiveness amid raw material inflation.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Icl Group Ltd

ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.

Read more on ICL

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY